Carl Dambkowski Sells 22,417 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 22,417 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21. Following the completion of the transaction, the director directly owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. The trade was a 30.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Friday, June 12th, Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock. The shares were sold at an average price of $70.11, for a total value of $882,194.13.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00.

Oruka Therapeutics Price Performance

ORKA stock traded up $1.42 during mid-day trading on Friday, hitting $69.89. 781,454 shares of the stock were exchanged, compared to its average volume of 1,072,342. The business has a fifty day moving average price of $63.01 and a 200 day moving average price of $43.76. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.26. Oruka Therapeutics, Inc. has a 12 month low of $10.77 and a 12 month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Barclays lifted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Monday, April 27th. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 14th. UBS Group upped their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, Piper Sandler reiterated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $131.30.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the second quarter valued at about $28,000. BNP Paribas Financial Markets lifted its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics in the third quarter worth about $39,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.